116 related articles for article (PubMed ID: 26887702)
21. Cost analysis of cryotherapy for metastatic disease.
Ray CE
J Vasc Interv Radiol; 2012 Jun; 23(6):778-9. PubMed ID: 22626268
[No Abstract] [Full Text] [Related]
22. Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
[No Abstract] [Full Text] [Related]
23. The Authors Respond.
Hansen RN; Hackshaw MD; Sullivan SD; Ramsey SD
J Manag Care Spec Pharm; 2015 Sep; 21(9):844. PubMed ID: 26536677
[No Abstract] [Full Text] [Related]
24. Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.
Vrdoljak E; Torday L; Szczylik C; Kharkevich G; Bavbek S; Sella A
Expert Opin Pharmacother; 2016; 17(1):93-104. PubMed ID: 26619144
[TBL] [Abstract][Full Text] [Related]
25. Current and predicted cost of metastatic renal cell carcinoma in Finland.
Purmonen T; Nuttunen P; Vuorinen R; Pyrhönen S; Kataja V; Kellokumpu-Lehtinen P
Acta Oncol; 2010 Aug; 49(6):837-43. PubMed ID: 20331406
[TBL] [Abstract][Full Text] [Related]
26. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma.
Chabot I; Rocchi A
Value Health; 2010; 13(6):837-45. PubMed ID: 20561332
[TBL] [Abstract][Full Text] [Related]
27. Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region.
Vrdoljak E; Ciuleanu T; Kharkevich G; Mardiak J; Mego M; Padrik P; Petruželka L; Purkalne G; Shparyk Y; Skrbinc B; Szczylik C; Torday L
Expert Opin Pharmacother; 2012 Feb; 13(2):159-74. PubMed ID: 22195646
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
Amdahl J; Diaz J; Sharma A; Park J; Chandiwana D; Delea TE
PLoS One; 2017; 12(6):e0175920. PubMed ID: 28636648
[TBL] [Abstract][Full Text] [Related]
29. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.
Gupta K; Miller JD; Li JZ; Russell MW; Charbonneau C
Cancer Treat Rev; 2008 May; 34(3):193-205. PubMed ID: 18313224
[TBL] [Abstract][Full Text] [Related]
30. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States.
Geynisman DM; Hu JC; Liu L; Tina Shih YC
Clin Genitourin Cancer; 2015 Apr; 13(2):e93-100. PubMed ID: 25450038
[TBL] [Abstract][Full Text] [Related]
31. ["... and now about the costs!"].
Rohde D
Aktuelle Urol; 2008 Jan; 39(1):2 p preceding table of contents. PubMed ID: 18303603
[No Abstract] [Full Text] [Related]
32. [Ⅳ. Current Economic Issues in Treatment for Metastatic Renal Cell Carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2019 Jan; 46(1):50-53. PubMed ID: 30765642
[No Abstract] [Full Text] [Related]
33. Evolving role of novel targeted agents in renal cell carcinoma.
Hutson TE; Figlin RA
Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
[TBL] [Abstract][Full Text] [Related]
34. [Biotherapies: toward a second revolution?].
Mouthon L
Presse Med; 2009 May; 38(5):746-8. PubMed ID: 19328647
[No Abstract] [Full Text] [Related]
35. Novel therapeutics for metastatic renal cell carcinoma.
Hutson TE; Figlin RA
Cancer; 2009 May; 115(10 Suppl):2361-7. PubMed ID: 19402059
[TBL] [Abstract][Full Text] [Related]
36. Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis.
Pitt M; Crathorne L; Moxham T; Bond M; Hyde C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):41-6. PubMed ID: 21047490
[TBL] [Abstract][Full Text] [Related]
37. [New treatment of metastatic renal cancer. The Danish Society of Clinical Oncology].
Sengeløv L; Geertsen PF;
Ugeskr Laeger; 2007 Mar; 169(12):1117. PubMed ID: 17394828
[No Abstract] [Full Text] [Related]
38. [Cancer of the kidney in adults. Economic aspects].
Prog Urol; 1997 Nov; 7(5):901-4. PubMed ID: 9458486
[No Abstract] [Full Text] [Related]
39. The role of socioeconomic status in renal cell carcinoma.
Hellenthal NJ; Bermejo CE
Urol Oncol; 2012; 30(1):89-94. PubMed ID: 21908209
[TBL] [Abstract][Full Text] [Related]
40. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Pouessel D; Culine S
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
